Your Article Summary
U.S. Army Botulinum Neurotoxin (BoNT) Medical Therapeutics Research Program: past accomplishments and future directions
Drug Development Research, 06/19/09
Larsen JC et al. - The development of small molecules for the treatment of BoNT has also been supported. Efforts have focused on molecules to inhibit nearly every aspect of BoNT pathogenesis. This would include toxin binding, translocation, catalytic activity, and recovery following intoxication. Several compounds capable of inhibiting toxin activity or mitigating the severity of paralysis have been identified.
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
Novartis, 11/25/09
Bayer CropScience signs Agreement with GVK Biosciences on early-stage research projects
BayNews International, 11/25/09
Reports Rate Ambulatory EHR Software
HealthDataManagement, 11/25/09
Article Search
Sponsor


See Latest Articles


